Gary Locke and Microsoft
The U.S. Department of Commerce has been given a high profile role in intellectual property policies in the Obama Administration. The Department is headed by Secretary of Commerce Gary Locke. Locke is the best known as the former two term governor of the State of Washington. After leaving the government, he has also been a lawyer and consultant, including to Microsoft. Here are a few data points on that relationship.
Continue Reading
WIPO Scoping Study on Copyright and Related Rights and the Public Domain (released May 2010)In May 2010 the WIPO Secretariat published a paper entitled “WIPO Scoping Study on Copyright and Related Rights and the Public Domain” prepared by Professor Séverine Dusollier (Professor, University of Namur, Belgium). This study was produced as an output of the WIPO Committee on Development and Intellectual Property’s (CDIP) thematic project on intellectual property and the public domain which is predicated upon Recommendations 16 and 20 of the Development Agenda. Part 1: Notes on the August 25, 2010 version of the ACTA consolidated textKEI has obtained a copy of the August 25, 2010 version of the ACTA consolidated negotiating text. This is Part 1 of our initial notes on the document. (Part 2 is available here.) (revised September 9, 2010) PreambleThe preamble in the August, 25, 2010 text includes 10 paragraphs, of which only 3 do not have brackets. EB101.R24: 1998 WHO EB proposal for the WHO Revised drug strategy101st Session Revised drug strategyThe Executive Board RECOMMENDS to the Fifty-first World Health Assembly the adoption of the following resolution: The Fifty-first World Health Assembly, Recalling resolutions WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14; Having considered the report of the Director-General on the revised drug strategy[1]; WHA 52.19, the Revised Drug StrategyA pdf copy of the resolution is attached to this page. THE FIFTY-SECOND WORLD HEALTH ASSEMBLY Agenda Item 13 Revised Drug StrategyThe Fifty-second World Health Assembly, Recalling resolution WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14; Having considered the report of the Director-General on the revised drug strategy[1]; May 27, 1998 Department of State cable: REVISED DRUG STRATEGY AT W.H.O.: ATMOSPHERICS OF THE DEBATE, AND RECOMMENDED PLAN OF ACTIONCONFIDENTIAL RELEASED IN FULL PAGE 01 GENEVA 03470 01 OF 09 271621Z ACTION 10-00 425261 271705Z /38 O 271615Z MAY 98 FM USMISSION GENEVA Timeline of privileges regarding the commercialization and use of knowledge. Part 2: 1980 to 1999Draft Timeline of privileged regarding the commercialization and use of knowledgeLunch with the ACTA negotiators, August 17, 2010On Tuesday, August 17, 2010, USTR organized a lunch between ACTA negotiators and civil society NGOs. There was not much notice. We received our invite to the lunch last Thursday. Representatives from KEI, Public Citizen, Oxfam, Public Knowledge and the American University program on intellectual property attended the event. U.S. Department of State cables regarding Brazil and pharmaceutical patents and prices – 1986-1987BackgroundBeginning in 1985, the United States government (USG) diplomatic and trade officials have engaged in wide ranging activities aimed at changing global norms for the protection of intellectual property rights, with a particular emphasis on the IPR protections for pharmaceutical products. This note reports on U.S. Department of State cables sent in 1986 and 1987, that discussed the U.S. government efforts to change policies in Brazil on the intellectual property protection for pharmaceutical products. The cables have been obtained by KEI with a FOIA request. Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 KEI Research Note 2010:4 August 12, 2010 Anne Mira Guha Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 1. Introduction Ritonavir is… Continue Reading |